3rd Hippo Pathway Targeted Drug Development Summit

The field of Hippo Pathway targeted drugs is seeing a surge of activity, with new clinical data being generated everyday and novel combinations being tested. The 3rd Hippo Pathway Targeted Drug Development Summit has been built alongside industry experts from the likes of Vivace Therapeutics, Orion Pharma, Insilico Medicine and more to return as the premier event for Hippo industry leaders focusing on developing innovative, safe, and effective therapies in oncology, fibrosis, and beyond.

Join over 20 global Hippo experts as we advance YAP, TAZ, and TEAD modulators towards clinical success - right from the comfort of your screen! This is your virtual hub to meet 80+ Hippo experts from across the globe gathering for data-led presentations, deep-diving panels, and interactive roundtables to advance the Hippo industry forward.

URLs:
Tickets: https://go.evvnt.com/2628622-2?pid=176 
Brochure: https://go.evvnt.com/2628622-3?pid=176

Time: 8:00 AM - 4:40 PM

Prices:
Drug Developer Pricing - Conference Only - On the Door: USD 2129.00,
Service Provider Pricing - Conference Only - On the Door: USD 2619.00,
Academic Pricing - Conference Only - On the Door: USD 1849.00

Speakers: John Lamar, Associate Professor, Albany Medical College, Shirley Guo, Director of Biology, BridGene Biosciences, Jidong Zhu, Co-Founder and Chief Executive Officer, Etern Therapeutics, Michelle Chen, Chief Business Officer, Insilico Medicine, Arianna Sabo, Head of Research and Discovery, QUANTRO Therapeutics GmbH, Srinivas Vinod Saladi, Assistant Professor of Cell and Cancer Biology, University of Toledo, College of Medicine and Life Sciences, Jeff Holden, Head of Structural Biology, Vilya Therapeutics, David Lagares, Chief Executive Officer and Founder, Zenon Biotech, Wanjin Hong, Professor and Chief Business Development Officer, Biomedical Research Council (BMRC), A*STAR, Ajaybabu Pobbati, Assistant Professor, Cleveland Clinic, Alissa Guarnaccia, Postdoctoral Researcher, Genentech, Carsten Hansen, Reader, Institute for Regeneration and Repair, University of Edinburgh, Shengli Dong, Executive Director, Biology, Tyk Medicines, Alessia Mira, Senior Scientist, Molecular Biotechnology Center, University of Torino, Melanie Frigault, Consultant, Translational Medicine, Vincerx Pharma, Federico Mauri, Principal Scientist, Boehringer Ingelheim, Zhi Liang Chu, Founder and Chief Executive Officer, Crossignal Therapeutics, Seung Hyun Jung, Team Leader, Targeted Oncology Research Team, Hanmi Pharma , Satu Juhila, Project Leader, Early Clinical Development Oncology, Orion Pharma, Chenglong Li, Nicholas Bodor Professor in Drug Discovery, University of Florida, Kari Kurppa, Principal Investigator, University of Turku, Neelesh Sharma, Chief Medical Officer, Vivace Therapeutics